However, for schizophrenia spectrum disorders (SSD), only a few trials have been conducted, mostly in outpatient settings.

Objectives: This study aimed to investigate feasibility, acceptability, and preliminary effectiveness of a four-week mindfulness-based group therapy (MBGT) for in-patients with SSD.

Methods: A pre-registered randomized controlled trial (RCT) was conducted at the in-patient ward for SSD. All measures were employed at baseline, post-intervention (4-weeks), and follow-up (12-weeks). The primary outcome was 'mindfulness'. Secondary outcomes were rater-blinded positive- and negative symptoms, depression, social functioning, as well as self-rated mindfulness, depression, anxiety, psychological flexibility, quality of life, and medication regime.

Results: N=40 participants were randomized into either four-week treatment-as-usual (TAU; n=19) or MBGT+TAU (n = 21). Protocol adherence was 95.2%, and the retention rate to treatments was 95%. ANCOVA analysis revealed significant improvements in the MBGT+TAU compared to TAU for the primary outcome and negative symptoms. Exploratory analyses showed medium-to-large intervention effects on secondary outcomes mindfulness, positive, negative, and depressive symptoms, psychological flexibility, quality of life, and social functioning for MBGT+TAU and small-to-moderate changes on positive symptoms and social functioning for TAU. No serious adverse effects were reported.

Conclusions: This study supports the feasibility and acceptability of MBGT for in-patients with SSD, including high protocol adherence and retention rates. A proof of concept of the MBIs and corresponding improvements on various clinical and process parameters warrant a fully powered RCT to determine effectiveness, cost-efficiency, and longitudinal outcomes of MBGT for SSD.

Disclosure: No significant relationships.

Keywords: randomized controlled trial; Schizophrenia spectrum disorders; mindfulness; psychotherapy

EPV0626

Insomnia associated with neutrophil/lymphocyte ratio in female patients with schizophrenia

G. Paniagua^{1,2,3*}, L. González-Blanco^{2,4,5}, F. Dal Santo^{1,2,6}, C. Martínez-Cao¹, C. Moya-Lacasa², M. Valtueña-García¹, E. Martín Gil¹, L. García-Alvarez^{4,5}, P.A. Saiz^{2,4,5}, M.P. García-Portilla^{2,4,5} and J. Bobes^{2,4,5}

¹Department Of Psychiatry, University of Oviedo, Oviedo, Spain;

²Psychiatry, SESPA Mental Health Services of Principado de Asturias, OVIEDO, Spain; ³Csm Eria, Servicio Salud Principado Asturias, University of Oviedo, Asturias, Oviedo, Asturias, Spain; ⁴Neuroscience And Sense Organs, ISPA HEALTH RESEARCH INSTITUTE OF THE PRINCIPALITY OF ASTURIAS, Oviedo, Spain; ⁵Department Of Psychiatry, University of Oviedo/CIBERSAM, Oviedo, Spain and ⁶Psychiatry, Hospital Universitario Central de Asturias, Oviedo, Spain

*Corresponding author.

doi: 10.1192/j.eurpsy.2021.2131

Introduction: Worse sleep quality and increased inflammatory markers in women with schizophrenia (Sch) have been reported (Lee et al. 2019). However, the physiological mechanisms underlying the interplay between sleep and the inflammatory pathways are not yet well understood (Fang et al. 2016).

Objectives: Analyze the relationship between Neutrophil/Lymphocyte (NLR), Monocyte/Lymphocyte (MLR) and Platelet/Lymphocyte (PLR) ratios, and insomnia in Sch stratified by sex.

Methods: Final sample included 176 Sch patients (ICD-10 criteria) [mean age: 38.9±13.39; males: 111(63.1%)]. Assessment: PANSS, Calgary Depression Scale (CDSS), and Oviedo Sleep Questionnaire (OSQ) to identify a comorbid diagnosis of insomnia based on ICD-10. Fasting counting blood cell were performed to calculate ratios. Statistics: U Mann-Whitney, logistic regression.

Results: Insomnia as comorbid diagnosis was present in 22 Sch (12.5%) with no differences between sex [14 males (12.6%), 8 females (12.3%)], neither in their age. Female patients with insomnia showed increased NLR [2.44±0.69 vs. 1.88±0.80, U=122.00 (p=0.034)]. However, no differences in PLR and MLR were found, neither in any ratio in males. Regression models using insomnia as dependent variable and covariates (age, PANSS-positive, PANSS-negative, CDSS) were estimated. Females: presence of insomnia was associated with NLR [OR=3.564 (p=0.032)], PANSS-positive [OR=1.263 (p=0.013)] and CDSS [OR=1.198 (p=0.092)]. Males: only PANSS-positive [OR=1.123 (p=0.027)] and CDSS scores [OR=1.220 (p=0.005)] were associated with insomnia.

Conclusions: NLR represent an inflammatory marker of insomnia in Sch but only in female patients. Improving sleep quality in these patients could help to decrease their inflammatory response.

Disclosure: No significant relationships.

Keywords: female; schizophrenia; Insomnia; Inflammation

EPV0628

Investigating the influence of thought interference and somatic passivity on outcomes in patients with psychosis

T. Magrangeas^{1*}, A. Kolliakou¹, J. Sanyal², R. Patel^{1,2} and R. Stewart^{1,2}

¹Institute Of Psychiatry, Psychology And Neuroscience, King's College London, London, United Kingdom and ²Biomedical Research Centre, South London and Maudsley NHS Foundation Trust, London, United Kingdom

*Corresponding author.

doi: 10.1192/j.eurpsy.2021.2132

Introduction: Of the many studies describing psychotic symptoms in schizophrenia, few have investigated their direct influence on prognosis.

Objectives: We aimed to apply natural language-processing (NLP) algorithms in routine healthcare records to identify reported somatic passivity and thought interference symptoms (thought broadcasting, insertion and withdrawal), and determine associations with prognosis by an analysis of routine outcomes.

Methods: Four algorithms were thus developed on de-identified mental healthcare data from a large south London provider and were applied to ascertain recorded symptoms over the three months following first presentation to that service in a cohort of patients with a primary schizophreniform disorder (ICD-10 F20-F29) diagnosis. The primary binary dependent variable for logistic regression analyses was any negative outcome (Mental Health Act section, >2